Caris Life Sciences (CAI) Stock Price & Analysis

CAI$23.04-0.92 -3.84%
BiotechnologyGrowth StockHigh Quality
Compare
Market cap$6.61BEnterprise value$8.73BRevenue (TTM)$1.05BMarket position—

Score

66
Bullish
Value
41
Quality
70
Growth
86

AI Analysis

Snapshot

Caris Life Sciences is a growth-led story right now — Growth 86/100 is the pillar doing the heavy lifting (overall 66/100) in Biotechnology. Under the hood: P/E 98.9, rich vs its own history, plus revenue compounding ~50% annually over recent years. Street targets still imply ~24% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

41
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

86
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

70
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Caris Life Sciences, Inc. (CAI) last printed $23.04. Equity value is $6.61B. Trailing earnings multiple 68.79. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2015201620172018201920202022202320242025
$249.67M$294.35M$348.39M$432.1M$416.54M$294.01M$258.49M$306.13M$412.26M$812.03M

About

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

Caris Life Sciences (CAI) Stock Price & Analysis

CAI price $23.04 -0.92 -3.84%

Ticker
CAI
Price
$23.04
Change
-0.92 -3.84%
Market cap
$6.61B
P/E
68.79
Forward P/E
93.81
Dividend yield
0.00%
Beta
0.70
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
66
Value
41
Quality
70
Growth
86

Stocklytics score rationale: value 41, quality 70, growth 86.

AI Score 65. Caris Life Sciences, Inc. has a market cap of approximately $9.39 billion and a high price-to-earnings ratio of about 98.9, indicating potential overvaluation

Insights · Forecast · Financials · Learn

Stocklytics home · Screener